KOSÉ Corporation

KOSÉ Corporation, together with its subsidiaries, manufactures, markets, and sells cosmetics primarily in Asia, the United States, and internationally. It offers cleansing, facial wash, toner, emulsion, cream, gel/serum, pack mask, lip care, and massage products. The company also provides sunscreen, fragrance, makeup goods, hair products, beauty supplements, and other cosmetics. It offers its cosmetics under the DECORTÉ, JILLSTUART, ADDICTION, INFINITY, Awake, tarte, ALBION, MIYABI, Paul & Joe, IGNIS, Elegance, INFIORE, ANNA SUI, Predia, iMPREA, X-Barrier, ACNEO, ASTALUXE, MAIHADA, LECHÉRI, ESPRIQUE, SEKKISEI, ONE BY KOSÉ, Visée, FASIO, NAILHOLIC, BIOLISS, Magnifique, CLEAR TURN, BIOLISS, Je l'aime, softymo, SUNCUT, MAKE KEEP MIST, and GRACE ONE brands. It offers its products through specialty cosmetic stores, department stores, cosmetics stores, mass retailers, drugstores, convenience stores, and other retail outlets, as well as e-commerce. KOSÉ Corporation was founded in 1946 and is headquartered in Tokyo, Japan.

KOSÉ Corporation trades as KSRYY on OTC. The company is classified in Consumer Defensive / Household & Personal Products and reports in USD.

The current profile places the business in Household & Personal Products. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $346.20B of revenue and $15.85B of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

KOSÉ Corporation can be compared against peers such as Société BIC S.A., B&M European Value Retail S.A., Greggs plc, Greggs plc, Ito En, Ltd., Kobayashi Pharmaceutical Co., Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.80B, beta of 0.01, and return on equity of +5.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

KSRYY currently shows total debt of $10.66B and beta of 0.01. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: F-6 POS (2026-01-07 00:00:00), F-6 POS (2025-12-23 00:00:00), F-6 POS (2025-12-23 00:00:00), F-6 POS (2025-12-17 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.kose.co.jp

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.